Articles related to DRUG SAFETY & INTERACTIONS

A systematic review of 43 randomized controlled trials found high-certainty evidence that multiple CGRP-targeted therapies reduced monthly migraine headache days by approximately 2 days versus placebo in adults with chronic migraine.

A two-sample analysis of GWAS data identified genetically predicted associations between six commonly prescribed medications and increased erectile dysfunction risk, while aspirin did not reach statistical significance after SNP exclusions.

A retrospective analysis of FDA postmarketing reports identified textural changes, pigmentary alteration, and subcutaneous fat loss as the most frequently reported adverse events following radiofrequency microneedling, with most cases occurring on the face and submental area.

Cotrimoxazole was associated with nearly twice the adverse event rate of fluoroquinolones in a retrospective study of 228 hospitalized men aged 75 or older with urinary tract infections, with acute kidney injury onset occurring at a median of six days post-initiation.

Hemarthrosis affects an estimated 70–80% of people with hemophilia and can progress to permanent joint damage, with pain management presenting a specific medication safety intersection point for pharmacists at the OTC counter and bedside.

The Tardive Dyskinesia Impact Scale showed high discrimination and precision across physical function and socioemotional domains in pooled data from 388 patients in the KINECT 3 and KINECT 4 valbenazine trials.